1 Min Read
Sept 27 (Reuters) - Lexicon Pharmaceuticals Inc
* Lexicon Pharmaceuticals initiates patient dosing in a phase 1 study of LX9211 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.